Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).

{"article_title":"Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance\/low-grade squamous intraepithelial lesion Triage Study (ALTS).","author":"Kulasingam, Shalini L , Kim, Jane J , Lawrence, William F , Mandelblatt, Jeanne S , Myers, Evan R , Schiffman, Mark , Solomon, Diane , Goldie, Sue J , ALTS Group","journal_title":"Journal of the National Cancer Institute","issn":"1460-2105 ; Electronic","isbn":"","publication_date":"20060118","volume":"98","issue":"2","first_page":"92","page_count":"9","accession_number":"16418511","doi":"10.1093\/jnci\/djj009","publisher":"Oxford University Press","doctype":"Journal Article; Research Support","subjects":"Oncoloy ","interest_area":["Obstetrics & Gynecology"," Oncology"],"abstract":"The ALTS (atypical squamous cells of undetermined significance [ASCUS] and low-grade squamous intraepithelial lesion [LSIL] Triage Study) suggests that, for women diagnosed with ASCUS, human papillomavirus (HPV) DNA testing followed by referral to colposcopy of only those women with oncogenic HPV (i.e., HPV DNA testing) is as effective at detecting cervical intraepithelial neoplasia (CIN) 3 or cancer (CIN3+) as referring all women with ASCUS for immediate colposcopy. We conducted a cost-effectiveness analysis of the ALTS trial to determine whether HPV DNA testing is a cost-effective alternative to immediate colposcopy or conservative management with up to three cytology examinations.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=16418511&authtype=shib&custid=ns346513"}